Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis (ALTER-G-001)

Clinical trial NCT05262335 · UNKNOWN

Trial details

NCT number: NCT05262335
Sponsor: Ruijin Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Gastrointestinal Tumors

Start date: 2021-12-01
Primary completion: 2023-12-01
Enrollment: 116

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.